These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The inhibitory effects of PGG and EGCG against the SARS-CoV-2 3C-like protease. Chiou WC; Chen JC; Chen YT; Yang JM; Hwang LH; Lyu YS; Yang HY; Huang C Biochem Biophys Res Commun; 2022 Feb; 591():130-136. PubMed ID: 33454058 [TBL] [Abstract][Full Text] [Related]
5. Identification of Potential Inhibitors of 3CL Protease of SARS-CoV-2 From ZINC Database by Molecular Docking-Based Virtual Screening. Abdusalam AAA; Murugaiyah V Front Mol Biosci; 2020; 7():603037. PubMed ID: 33392261 [TBL] [Abstract][Full Text] [Related]
6. In silico studies of selected multi-drug targeting against 3CLpro and nsp12 RNA-dependent RNA-polymerase proteins of SARS-CoV-2 and SARS-CoV. Udofia IA; Gbayo KO; Oloba-Whenu OA; Ogunbayo TB; Isanbor C Netw Model Anal Health Inform Bioinform; 2021; 10(1):22. PubMed ID: 33786291 [TBL] [Abstract][Full Text] [Related]
8. Development of a simple, interpretable and easily transferable QSAR model for quick screening antiviral databases in search of novel 3C-like protease (3CLpro) enzyme inhibitors against SARS-CoV diseases. Kumar V; Roy K SAR QSAR Environ Res; 2020 Jul; 31(7):511-526. PubMed ID: 32543892 [TBL] [Abstract][Full Text] [Related]
9. QSAR based virtual screening derived identification of a novel hit as a SARS CoV-229E 3CL Jawarkar RD; Bakal RL; Zaki MEA; Al-Hussain S; Ghosh A; Gandhi A; Mukerjee N; Samad A; Masand VH; Lewaa I Arab J Chem; 2022 Jan; 15(1):103499. PubMed ID: 34909066 [TBL] [Abstract][Full Text] [Related]
10. The molecular mechanism of non-covalent inhibitor WU-04 targeting SARS-CoV-2 3CLpro and computational evaluation of its effectiveness against mainstream coronaviruses. Wu J; Zhang HX; Zhang J Phys Chem Chem Phys; 2023 Sep; 25(35):23555-23567. PubMed ID: 37655706 [TBL] [Abstract][Full Text] [Related]
11. Cell-Based High-Throughput Screening Protocol for Discovering Antiviral Inhibitors Against SARS-COV-2 Main Protease (3CLpro). Rothan HA; Teoh TC Mol Biotechnol; 2021 Mar; 63(3):240-248. PubMed ID: 33464543 [TBL] [Abstract][Full Text] [Related]
12. Synthesis of Dihydrobenzofuro[3,2-b]chromenes as Potential 3CLpro Inhibitors of SARS-CoV-2: A Molecular Docking and Molecular Dynamics Study. Gorai S; Junghare V; Kundu K; Gharui S; Kumar M; Patro BS; Nayak SK; Hazra S; Mula S ChemMedChem; 2022 Apr; 17(8):e202100782. PubMed ID: 35112482 [TBL] [Abstract][Full Text] [Related]
14. TAT-peptide conjugated repurposing drug against SARS-CoV-2 main protease (3CLpro): Potential therapeutic intervention to combat COVID-19. Ansari MA; Jamal QMS; Rehman S; Almatroudi A; Alzohairy MA; Alomary MN; Tripathi T; Alharbi AH; Adil SF; Khan M; Shaheer Malik M Arab J Chem; 2020 Nov; 13(11):8069-8079. PubMed ID: 34909057 [TBL] [Abstract][Full Text] [Related]
15. Effective inhibition of coronavirus replication by Xu H; Li J; Song S; Xiao Z; Chen X; Huang B; Sun M; Su G; Zhou D; Wang G; Hao R; Wang N Front Biosci (Landmark Ed); 2021 Oct; 26(10):789-798. PubMed ID: 34719206 [No Abstract] [Full Text] [Related]
16. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening. Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740 [TBL] [Abstract][Full Text] [Related]
17. A comprehensive review on promising anti-viral therapeutic candidates identified against main protease from SARS-CoV-2 through various computational methods. Singh E; Khan RJ; Jha RK; Amera GM; Jain M; Singh RP; Muthukumaran J; Singh AK J Genet Eng Biotechnol; 2020 Nov; 18(1):69. PubMed ID: 33141358 [TBL] [Abstract][Full Text] [Related]